Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tramadol hydrochloride + gamma-aminobutyric acid
- Development stage
- Approved
- Lead developer
- Physician Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Tramadol hydrochloride + gamma-aminobutyric acid** is a small-molecule combination corresponding to the analgesic opioid tramadol hydrochloride administered together with gamma-aminobutyric acid as part of a proprietary amino-acid blend in the Theramine medical food component of the THERATRAMADOL-90 kit distributed by Physician Therapeutics. In the cited context, the combination is positioned for the dietary management of pain and inflammation rather than as an FDA-approved fixed-dose pharmaceutical product. Mechanistically, tramadol is a centrally acting analgesic with opioid receptor agonist activity and inhibition of monoamine reuptake, while gamma-aminobutyric acid is included as a nutritional or nutraceutical component rather than a well-defined approved analgesic active ingredient in this specific product configuration.
- Other names
- tramadol hydrochloride + gamma-aminobutyric acid
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on tramadol hydrochloride + gamma-aminobutyric acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tramadol hydrochloride + gamma-aminobutyric acid.